Aizon | January 25, 2022
On January 24, Aizon announced the introduction of its new asset tracking tool for the pharmaceutical and biotech industries. Aizon Asset Health is built on Aizon's GxP-compliant AI SaaS Platform. It performs intelligent historical maintenance analysis, continuously monitors the condition of critical assets in real-time, identifies potential problems, and provides actionable maintenance recommendations to keep equipment operating at peak performance. This data-driven approach to maintenance lowers maintenance costs, minimizes unexpected downtime, and maximizes product output, thus maximizing the potential of Smart Pharma Manufacturing.
Maintaining manufacturing equipment in good operating order may be costly and inefficient. A schedule-based approach to maintenance frequently results in the wasteful repair or replacement of equipment that is still operating in acceptable conditions or the catastrophic failure of equipment owing to undiscovered faults. This might result in production interruptions, product rejection, and a longer time to market, and product compromise. That is, guaranteeing that any operation is executed correctly the first time and every time. Combining sophisticated analytics and multivariate analysis with artificial intelligence, the Aizon Asset Health program improves unexpected downtime reduction beyond today's industry standard, eventually lowering maintenance costs while increasing asset dependability and performance.
"Pharmaceutical manufacturers and biotech companies are under tremendous pressure to maximize their return on investment and to reduce unplanned downtime. However, the traditional schedule-based maintenance approach tends to fall short in terms of gaining control of downtime and the high costs associated with replacing equipment in an effort to achieve better performance, Our Asset Health application enables our customers to harness the power of their equipment and environmental data to slash maintenance costs, optimize equipment performance, enhance product output, and improve product quality."
-John Vitalie, CEO, Aizon
Monitoring Intelligent, Real-Time Assets Across Equipment and Facilities
The Aizon Asset Health application enables pharmaceutical and biotech organizations to employ predictive analytics to monitor their assets' health and receive advanced warnings on their problems based on the solution's prescriptive and conditional data-driven insights. These actionable insights enable operators and maintenance teams to respond and intervene in real-time, ensuring the continued operation of manufacturing lines. In addition, asset Health is a cloud-native application that can be expanded across various sites and regions and maintains a history and condition of every piece of equipment.
This enables pharmaceutical and biotechnology organizations to assure total asset integrity, maintain ideal facility conditions (such as temperature, humidity, and vibration), forecast the projected life of equipment, and track the energy utilized by an asset and its CO2 emissions. Furthermore, this vital information is aggregated on a single dashboard tailored to meet every firm's particular asset care requirements.
"Demands for pharmaceutical manufacturing have never been higher. The Aizon Asset Health application helps manufacturers prevent unplanned downtime and maximize product quality and yield Aizon Asset Health taps into real-time sensor data, consolidates it, and leverages AI to generate alarms and/or actionable insights to optimize asset performance. It’s a game changer for the industry. "
-Andy Alasso, SVP Product, Aizon.
Essentium, Inc., Hephzibah | July 13, 2020
Essentium, Inc., a leading innovator of industrial additive manufacturing (AM) solutions, today announced a distribution partnership with Hephzibah, prominent South Korean 3D printing specialist, to advance additive manufacturing in South Korea.
The combination of Hephzibah’s best-in-class service, customer support, and use-case specific expertise, together with the ground-breaking speed and economics of the Essentium High Speed Extrusion (HSETM) 3D Printing Platform will help resolve many of the historic barriers to widespread adoption of industrial-scale AM and to advance additive manufacturing in South Korean market. Manufacturing firms in South Korea recognize that adding 3D printing to their factory floors could save billions in production costs.
However, they face significant obstacles to using 3D printing for large-scale production, such as the strength of parts, speed and scale of production, and economics. The Essentium and Hephzibah partnership will deliver AM solutions, based on open ecosystems, that produce parts with the strength, speed, and scale customarily associated with injection-moulding and with vastly improved economics.
Moderna, ROVI | July 10, 2020
Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines, and Laboratorios Farmacéuticos Rovi, S.A. (BME: ROVI), a pan-European pharmaceutical company specializing and engaging in the research, development, contract manufacturing and marketing of small molecules and biological specialties, today announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA vaccine candidate against COVID-19 (mRNA-1273) at ROVI’s facility in Madrid, Spain.
As part of the agreement, ROVI will provide vial filling and packaging capacity by procuring a new production line and equipment for compounding, filling, automatic visual inspection and labeling to support production of hundreds of millions of doses of the vaccine candidate intended in principle to supply markets outside of the U.S. starting in early 2021. ROVI will also hire additional staffing required to support manufacturing operations and production.